Victrix Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Victrix Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.97M	Hold	4,766	–	–	1.25%	26
2026 Q1	$3.68M	Sell	4,766 -134	-3%	-$103K	1.34%	29
2025 Q4	$3.78M	Hold	4,900	–	–	1.46%	27
2025 Q3	$2.76M	Hold	4,900	–	–	1.51%	24
2025 Q2	$2.57M	Hold	4,900	–	–	1.14%	31
2025 Q1	$3.11M	Hold	4,900	–	–	1.63%	24
2024 Q4	$3.49M	Buy	+4,900	New	+$4.11M	2.52%	13

Other funds holding REGN

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Victrix Investment Advisors's REGN Position: Q2 2026 in Review

Victrix Investment Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 4,766 shares worth $2.97M. The position accounts for 1.25% of the portfolio, ranked #26.

Victrix Investment Advisors first reported a position in REGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.78M in Q4 2025. 675 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Victrix Investment Advisors held 4,766 shares of Regeneron Pharmaceuticals worth $2.97M as of Q2 2026.
Victrix Investment Advisors left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up 1.25% of Victrix Investment Advisors's portfolio in Q2 2026, its #26 holding.
Victrix Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Victrix Investment Advisors's Regeneron Pharmaceuticals position peaked at $3.78M in Q4 2025.
675 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Victrix Investment Advisors's 13F filing for Q2 2026, filed 8 Jul 2026.